Teva Pharmaceutical Industries Ltd ADR Stock
The price for the Teva Pharmaceutical Industries Ltd ADR stock decreased slightly today. Compared to yesterday there is a change of -€0.100 (-0.640%).
With 13 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 18 € there is a slightly positive potential of 15.38% for Teva Pharmaceutical Industries Ltd ADR compared to the current price of 15.6 €.
Our community identified positive and negative aspects for Teva Pharmaceutical Industries Ltd ADR stock for the coming years. 2 users see the criterium "Management" as a plus for the Teva Pharmaceutical Industries Ltd ADR stock. On the other hand our users think that "Conscious of the environment" could be a problem in the future.
Pros and Cons of Teva Pharmaceutical Industries Ltd ADR in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
S********** s********
Cons
?
G***** c******* t* c**********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Teva Pharmaceutical Industries Ltd ADR vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Teva Pharmaceutical Industries Ltd ADR | -0.640% | 1.961% | 18.182% | 131.454% | 67.382% | 79.724% | 101.031% |
Bayer AG ADR | 2.290% | -2.963% | -0.758% | -50.000% | -23.837% | -50.000% | -50.000% |
Roche Holding AG ADR | 1.620% | 1.262% | 5.554% | -20.397% | -8.789% | -17.553% | - |
GSK plc ADR | 1.470% | -0.481% | 8.377% | 31.013% | 23.214% | 3.500% | -4.277% |
Comments
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at Bank of America Co. from $18.00 to $21.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $20.00 price target on the stock, up previously from $19.00.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at Barclays PLC from $17.00 to $20.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat